Back to Results

CASI Pharmaceuticals Inc (CASIF)

CASI Pharmaceuticals Inc is a Beijing-based biopharmaceutical company whose common stock trades on OTC Markets under the symbol CASI.F. Founded in 1991, the company develops and commercializes therapeutics and pharmaceutical products in China, the United States, and other international markets. Its marketed product portfolio includes EVOMELA, an intravenous formulation of melphalan used in conditioning before stem cell transplantation and as palliative treatment for multiple myeloma, as well as Thiotepa, a chemotherapeutic agent with several indications, including use before certain allogeneic hematopoietic stem cell transplants. CASI’s hematology and oncology pipeline includes CNCT19, BI-1206, CB-5339, and CID-103. The company also has licensing agreements with Juventas Cell Therapy, BioInvent International, Black Belt Therapeutics, Cleave Therapeutics, and Acrotech Biopharma related to EVOMELA development and commercialization.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score
OTC-CASI.F
$0.16
27.3% Upside
Undervalued
$4 3,005.6% Upside
Not available
Bargain
Weak
0.0%
November 13, 2026
0.1x
2.648 M
37.664 M
93.9%
47.3%
-147.8
Valuation • Fair Value

CASI Pharmaceuticals Inc (OTC-CASI.F) Fair Value by Valuation Model

Review the available estimates for CASI Pharmaceuticals Inc (OTC-CASI.F), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.16

Estimated upside of 27.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.11

Discounted cash flow valuation reference.

Comps Fair Value

$0.18

Comparable-company valuation reference.

Analyst Price Target

$4 3,005.6% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 5 available valuation references for CASI Pharmaceuticals Inc (OTC-CASI.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for CASI Pharmaceuticals Inc (OTC-CASI.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

20.114 M

Current operating scale indicator.

Revenue Forecast

20.712 M

Forward revenue estimate.

EBITDA

-37.616 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review CASI Pharmaceuticals Inc (OTC-CASI.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CASI Pharmaceuticals Inc (OTC-CASI.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-13.12

No elevated caution signal from this screen.

Altman Z-Score

-147.8

Lower score that deserves closer risk review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CASI Pharmaceuticals Inc (OTC-CASI.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CASI Pharmaceuticals Inc (OTC-CASI.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for CASI Pharmaceuticals Inc (OTC-CASI.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CASI Pharmaceuticals Inc (OTC-CASI.F) Stock Forecast & Technical Outlook

Review CASI Pharmaceuticals Inc (OTC-CASI.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for CASI Pharmaceuticals Inc (OTC-CASI.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CASI Pharmaceuticals Inc (OTC-CASI.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, CASI Pharmaceuticals Inc (OTC-CASI.F) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

CASI Pharmaceuticals Inc (OTC-CASI.F) Stock FAQ

Data-supported answers about CASI Pharmaceuticals Inc (OTC-CASI.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.16
Estimated upside 27.3%
Valuation Rating
Undervalued
Estimated upside of 27.3%
Analyst Target
$4 3,005.6% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for CASI Pharmaceuticals Inc (OTC-CASI.F) is $0.16. This implies an estimated upside of 27.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 27.3% versus the current market price.

The available analyst price target for CASI Pharmaceuticals Inc (OTC-CASI.F) is $4 3,005.6% Upside.

The current financial health read for CASI Pharmaceuticals Inc (OTC-CASI.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CASI Pharmaceuticals Inc (OTC-CASI.F) is November 13, 2026.

The latest available data indicates no current dividend yield for CASI Pharmaceuticals Inc (OTC-CASI.F).

The current market capitalization listed for CASI Pharmaceuticals Inc is 2.648 M.

The current enterprise value listed for CASI Pharmaceuticals Inc is 37.664 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CASI Pharmaceuticals Inc is OTC-CASI.F, and the stock is listed on OTC Markets.

CASI Pharmaceuticals Inc (OTC-CASI.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for CASI Pharmaceuticals Inc is 93.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CASI Pharmaceuticals Inc is 47.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B